Opportunity to undertake an MSc in Health Economics at the University of London

By HEOR Staff Writer

February 10, 2023

Opportunity to undertake an MSc in Health Economics at the University of London. Apply for a Fellowship Programme by 30 April 2023.

The Office of Health Economics (OHE) provides various forms of support to the upcoming generation of health economists in order to fulfil our philanthropic goals. They have established an MSc Fellowship Programme in collaboration with City, University of London, and a PhD Programme at LSE, London School of Economics and Political Science, for individuals interested in pursuing postgraduate studies in health economics.

Their objective is to ensure the continued role of health economics in high-quality, evidence-based health policy decision-making and to strengthen and advance the discipline’s future.

For further information, please visit:

Reference url

Recent Posts

PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications

By João L. Carapinha

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies

By João L. Carapinha

April 23, 2026

Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...